Abstract:It has been realized for more than fifty years that patients receiving blood transfusions are at risk of developing hepatitis.' Attention to the possible causes of hepatic injury associated with blood transfusion excluded non-infectious problems, such as hepatic congestion, iron overload or chemical contaminants. Further studies in humans and animals soon confirmed that the hepatitis was due to a filterable infectious agent, too small to be anything larger than a virus.2 Serological tests for the viruses causing hepatitis B were developed in 1965 and for hepatitis A in 1973, and it was then realized that post-transfusion hepatitis was not related to either of these agents, or to any other known viruses.3 At this time, the term 'non-A non-B' hepatitis was first coined in an attempt to label this presumed hepatic infection. Identifying the agent responsible so that serological tests can be developed to screen blood and blood products for the presence of this agent is of prime importance, as non-A non-B (NANB) hepatitis is a major cause ofmorbidity. Acute fulminant NANB hepatitis has a higher fatality rate than any other form of viral hepatitis,4 and it has also been estimated that between 40-50% ofpatients acquiring NANB infection will develop chronic hepatitis, with 15-20% of these subjects progressing to cirrhosis.5 It has been estimated that in the USA approximately 6000 patients per annum develop cirrhosis as a direct consequence ofchronic NANB hepatitis.6 For the past decade, many groups of workers have endeavoured to identify the agent(s) responsible for this disease. In spite of the spectacular advances in molecular biology which have paralleled the same period, it is only within the past 2 years that a breakthrough has occurred. Part of the genome of an RNA virus (related to the togaand flaviviridae) that is responsible for many, though not all, cases ofNANB infection has been sequenced. This has been labelled hepatitis C virus, and studies indicate that it is responsible for approximately 70-95% of cases of parenterally transmitted non-A non-B hepatitis. This still leaves a significant proportion of cases presumed due to another NANB agent. Within the past year, molecular biologists in the USA have also cloned a different RNA virus which is believed to be responsible for the most cases of enterally transmitted NANB infections, and has been provisionally termed hepatitis E.6a Although identification and characterization of the NANB agents is not yet complete, attempts have still been made to treat this disease, in view of the high morbidity associated with this disease. Recent trials of alpha-interferons have given very encouraging results and hold out hope for a significant improvement in the prognosis of affected individuals. This review looks at recent studies on the nature of this disease, the latest attempts at isolating the causative agent(s), and, lastly, attempts to suppress and/or eliminate this infection.

Isolation of Streptococcus zooepidemicus from a bald eagle (Haliaeetus leucocephalus).

When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy

Liposome-Based Drug Delivery Systems in Cancer Immunotherapy

[Burnout syndrome in nursing: etiology, complications, prevention].

Lipid-based Nanoparticles As Drug Delivery Systems for Cancer Immunotherapy.

Recent advancements in nanomedicine based lipid metabolism for tumour immunotherapy

Liposome-based nanomedicine for immune checkpoint blocking therapy and combinatory cancer therapy

Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments

Nano Drug Delivery System for Tumor Immunotherapy: Next-Generation Therapeutics

Liposomes-enabled cancer chemoimmunotherapy

Application of lipid nanovesicle drug delivery system in cancer immunotherapy

Immunocyte Membrane-Derived Biomimetic Nano-Drug Delivery System: a Pioneering Platform for Tumour Immunotherapy

Lipid-Based Nanocarriers: Bridging Diagnosis and Cancer Therapy

Nanomaterial-based cancer immunotherapy: enhancing treatment strategies

Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy

Immunocyte Membrane-Coated Nanoparticles for Cancer Immunotherapy

Lipid Nanoparticles in Lung Cancer Therapy

Membrane-Coated Biomimetic Nanoparticles: A State-of-the-Art Multifunctional Weapon for Tumor Immunotherapy

Parenterally acquired non-A non-B hepatitis ten years on: advances in diagnosis and therapy.

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment